Amneal Pharmaceuticals, Inc. Stock News

SACRAMENTO, Calif. — California will soon begin selling its own generic version of Narcan — the drug that can save someone's life during an opioid overdose — under a deal announced Monday by Dem

Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t

Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t

The headline numbers for Amneal (AMRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.23 per share a year ago.

Beyond analysts' top -and-bottom-line estimates for Amneal (AMRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed t

January's payrolls report shows 353,000 jobs

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its fourth quarter and full year 2023 financial results on Friday, March 1

Pharmaceutical companies, GSK (GSK), Amneal Pharmaceuticals (AMRX) and Kaléo have agreed to delist some of their patents from the FDA's orange book. GSK withdrew four inhaler patents and Amneal withd

Amneal Pharmaceuticals' stock price has been on a strong bull run, now exceeding $5 per share and up over >145% this year. The company experienced losses in 2018 and 2019 but has since seen improvemen

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Anthony DiMeo - Head-Investor Relations Chirag Patel - Co-Founder & Co-Chief

Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.